• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rivar Teva
    / SLE


    Active Ingredient
    Rivaroxaban 2.5 mg, 10 mg , 15 mg, 20 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    28, 30, 56, 60, 100, 250 x 2.5 mg

    not in the basket chart 38146 18679

    Film Coated Tablets

    28, 30, 56, 60, 100, 250 x 10 mg

    not in the basket chart 38132 18677

    Film Coated Tablets

    28, 30, 56, 60, 100, 250 x 15 mg

    not in the basket chart 38131 18676

    Film Coated Tablets

    28, 30, 56, 60, 100, 250 x 20 mg

    not in the basket chart 38145 18678

    Related information


    Dosage

    Dosage must be adjusted individually according to the patient’s medical condition. Please refer to the patient leaflet for the complete information.


    Indications

    Rivaroxaban 2.5 mg:
    Rivaroxaban 2.5 mg, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
    Rivaroxaban 2.5 mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
    Rivaroxaban 10 mg:
    Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
    Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), in adults (following completion of at least 6 months therapy for DVT or PE).
    Rivaroxaban 15 mg and 20 mg:
    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
    Treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.


    Contra-Indications

    Hypersensitivity to rivaroxaban or to any of the other ingredients.
    Excessive bleeding.
    Disease or condition in an organ of the body that increases the risk of serious bleeding (such as: stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes).
    Concomitant treatment with other anticoagulants (e.g. warfarin, dabigatran, apixaban or heparin), except under specific circumstances of changing from one anticoagulant to another or while receiving heparin through a venous or arterial line to keep it open.
    Liver disease which leads to an increased risk of bleeding.
    Pregnancy or breastfeeding.
    Please refer to the patient leaflet for the complete information.


    Special Precautions

    Please refer to the patient leaflet for the complete information.


    Side Effects

    Please refer to the patient leaflet for the complete information.


    Drug interactions

    Please refer to the patient leaflet for the complete information.


    Pregnancy and Lactation

    Please refer to the patient leaflet for the complete information.


    Overdose

    Please refer to the patient leaflet for the complete information.


    Important notes

    Doses of 15 mg and 20 mg must be taken with food and
    swallowed with water.
    This medicinal product may cause dizziness (a common side effect) or fainting (an uncommon side effect). Do not drive, ride a bicycle, use tools or operate machinery while using this medicinal product if you experience these symptoms.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    Licence holder
    CLOSE